Akoya Biosciences Inc (NAS:AKYA)
$ 2.8 0.03 (1.08%) Market Cap: 138.60 Mil Enterprise Value: 176.59 Mil PE Ratio: 0 PB Ratio: 6.22 GF Score: 40/100

Akoya Biosciences Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 13, 2021 / 09:00PM GMT
Release Date Price: $14.61 (+2.24%)
Tejas Rajeev Savant
Morgan Stanley, Research Division - Equity Analyst

Good evening, everyone. Thanks for joining us on day 3 of our Healthcare Conference. I'm Tejas Savant, and I cover the life science tools and diagnostics sector here at Morgan Stanley.

Delighted to have Akoya join us today. And representing the company, we have Brian McKelligon, CEO; and Joe Driscoll, CFO. So welcome, gents. Before we get started, a quick disclosure statement to read. Please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures.

If you have any questions, please do reach out to your sales rep. So Brian, I mean, before we get into the weeds, I mean, just for folks not as familiar with the story, could you provide a brief overview of the history of the company, how the 2 parts of the portfolio sort of like came together. And a highlight what you view as some of the key milestones you've achieved over the last 12 months or so besides the IPO, of course.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot